Andersen Tawil syndrome: genes and variants
Explore variant evidence for Andersen Tawil syndrome across 1 analyzed protein (KCNJ2). Linked ClinVar records include 34 pathogenic or likely pathogenic variants, 166 variants of uncertain significance and 25 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-10-15. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Andersen Tawil syndrome
KCNJ2: Inward rectifier potassium channel 2
Its inward-rectifier current stabilizes the resting membrane potential in cardiac and skeletal muscle and contributes to terminal cardiac repolarization. Loss-of-function variants cause Andersen-Tawil syndrome, while gain-of-function variants can cause short-QT syndrome.
34 ClinVar pathogenic / likely pathogenic and 191 uncertain variants in KCNJ2 have source records linked to Andersen Tawil syndrome. Association strength is not clinical gene validity.
Where Andersen Tawil syndrome variants cluster
- KCNJ2 Selectivity filter (positions 142–147): 5 of 33 ClinVar pathogenic / likely pathogenic variants, 10.8× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Andersen Tawil syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| KCNJ2 R82Q | 82 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R82W | 82 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G144S | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R312H | 312 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R312C | 312 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G144A | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G144D | 144 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218W | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218P | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R218Q | 218 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G146S | 146 | Pore-forming | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R189G | 189 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic (★★) |
| KCNJ2 G300V | 300 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 R67Q | 67 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| KCNJ2 T75K | 75 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 T75R | 75 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D78Y | 78 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D78N | 78 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 P186Q | 186 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic (★) |
| KCNJ2 T305A | 305 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 T309I | 309 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 Y145C | 145 | Pore-forming | Pathogenic / likely pathogenic (★) |
| KCNJ2 G215D | 215 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 N216Y | 216 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 E299G | 299 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 R260H | 260 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 C54F | 54 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 D71V | 71 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| KCNJ2 L90R | 90 | Transmembrane | Pathogenic / likely pathogenic (★) |
| KCNJ2 D172N | 172 | Transmembrane | Pathogenic / likely pathogenic (★) |
| KCNJ2 T192A | 192 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic (★) |
| KCNJ2 P186L | 186 | Polyphosphoinositide (PIP2)-binding | Pathogenic / likely pathogenic |
| KCNJ2 T305P | 305 | Cytoplasmic | Pathogenic / likely pathogenic |
| KCNJ2 V302M | 302 | Cytoplasmic | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Andersen Tawil syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| KCNJ2 G144V | 144 | Pore-forming | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; G144A at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 T192I | 192 | Polyphosphoinositide (PIP2)-binding | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; T192A at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 R218L | 218 | Cytoplasmic | Conflicting reports (★) | +6: 5 other pathogenic changes within 3 positions; R218W at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 R189K | 189 | Polyphosphoinositide (PIP2)-binding | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; R189G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| KCNJ2 G215C | 215 | Cytoplasmic | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; G215D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.98 |
| KCNJ2 G146D | 146 | Pore-forming | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; G146S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 D78H | 78 | Cytoplasmic | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; D78Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| KCNJ2 N216I | 216 | Cytoplasmic | Uncertain (★) | +6: 5 other pathogenic changes within 3 positions; N216Y at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.99 |
| KCNJ2 R189T | 189 | Polyphosphoinositide (PIP2)-binding | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; R189G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
Diseases related to Andersen Tawil syndrome
- Long QT syndrome, also linked to KCNJ2
- Cardiac arrhythmia, also linked to KCNJ2
- Short QT syndrome, also linked to KCNJ2
- Familial atrial fibrillation, also linked to KCNJ2
Frequently asked questions
Which genes have records linked to Andersen Tawil syndrome?
This view contains 1 analyzed proteins: KCNJ2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 34 pathogenic or likely pathogenic variants, 166 variants of uncertain significance and 25 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 9 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 240 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center